Which molecular forms of LDN exist, which forms can be manufactured, and what might this mean for Low Dose Naltrexone?

LDN RESEARCH TRUST

Naltrexone: The Molecule in the Bottle Is Only the Beginning

What eighteen years of chemistry can teach us about LDN

SCIENCE  •  PEOPLE  •  POSSIBILITIES

 

A scientific question with a much bigger answer

There has recently been discussion about the stereochemistry of naltrexone: which molecular forms exist, which forms can be manufactured, and what this might mean for Low Dose Naltrexone (LDN).

It is an important scientific question—but it is considerably more complicated than it may first appear.

Naltrexone is a three-dimensional molecule, so its stereochemistry matters. Different stereochemical forms can have very different biological properties. Different manufacturing routes approach that stereochemistry in different ways. And once naltrexone enters the human body, it undergoes further stereoselective chemistry.

Perhaps most importantly, our understanding of this chemistry has developed substantially since the early years of LDN.

So what can we actually say with confidence?

Where the original information came from

In 2008, people involved in the early LDN community discussed the manufacture of naltrexone directly with Sanofi. Our historical understanding of those discussions was that the manufacturing process being described could not selectively produce a single enantiomer and instead resulted in racemic material.

That account is part of the historical record of how the LDN community understood naltrexone chemistry at the time. However, the underlying 2008 correspondence and manufacturing records are not reproduced here, so the historical account should remain clearly attributed rather than presented as independently verified manufacturing data.

That distinction matters. Eighteen years later, published chemistry gives us a much richer picture of the possible manufacturing routes—but it does not allow us to reconstruct every technical detail of a conversation or a particular commercial batch from 2008.

Sanofi was working on naltrexone chemistry at the same time

There is, however, a useful piece of public historical evidence.

Sanofi-Aventis France filed patent material concerning the preparation of N-alkyl naltrexone halides. The patent family records a French priority date of 21 September 2006, a PCT filing in September 2007, and publication of WO2008/034973 on 27 March 2008.

The patent is relevant because stereochemistry is explicitly discussed in connection with N-alkyl naltrexone derivatives. In particular, it distinguishes R and S configurations at the quaternary nitrogen of N-methyl naltrexone and notes different biological activity associated with those configurations.

That demonstrates that stereochemical control was a real and documented issue in Sanofi's naltrexone-related chemistry during this period.

It does not, however, prove that ordinary pharmaceutical naltrexone supplied to patients in 2008 was a 50:50 mixture of (+)- and (−)-naltrexone. Nor does the patent by itself establish exactly which manufacturing process was being discussed with us in 2008.

The responsible conclusion is therefore a narrower one: the public patent record confirms that Sanofi was working on naltrexone-related manufacturing chemistry in which stereochemical outcomes mattered, while the precise meaning of the 2008 technical discussion cannot now be reconstructed without the original correspondence and analytical records.

There isn't just one way of making naltrexone

Modern synthetic chemistry makes the story even more interesting.

Prevalent commercial approaches to (−)-naltrexone have historically used (−)-thebaine as a starting material. Because thebaine already contains substantial stereochemical information, those routes are fundamentally different from a synthesis that begins with simple achiral building blocks.

In 2019, Dongbang, Pedersen and Ellman reported an asymmetric total synthesis of (−)-naltrexone that did not proceed through thebaine. Their route began with simple achiral precursors and used catalytic enantioselective Sharpless dihydroxylation to introduce stereogenic centres. The reported synthesis had a 17-step longest linear sequence.

The authors also noted that, because the relevant stereochemistry was established through the asymmetric step, the strategy could in principle provide access to either enantiomer.

That is an important lesson: the question “How is naltrexone made?” has no single universal answer. The answer depends on the starting material, the route, and where stereochemical information enters the synthesis.

The other enantiomer is scientifically interesting

The conventional opioid-antagonist activity of naltrexone is strongly stereoselective, with (−)-naltrexone being the pharmacologically important opioid-receptor antagonist.

Its mirror-image (+)-enantiomer has much weaker activity at classical opioid receptors. But calling it simply “inactive” would miss an important area of research.

Experimental studies have investigated (+)-naltrexone as an antagonist of Toll-like receptor 4 (TLR4)-associated signalling, including interactions involving the MD-2 component of the receptor complex. These findings are largely mechanistic and preclinical; they should not be interpreted as establishing that TLR4 activity explains the clinical effects of LDN.

That distinction is crucial.

The chemistry tells us that mirror-image molecules can behave very differently. It also gives researchers useful tools for separating opioid-receptor mechanisms from other proposed biological pathways.

But a mechanistic possibility is not the same thing as a demonstrated explanation for LDN's clinical effects.

And then we swallow the tablet

This may be the most important part of the story.

A medicine is not pharmacologically defined only by the molecule sitting inside its container. Once naltrexone is administered, the body absorbs, distributes and metabolises it.

Human metabolism is itself stereoselective.

One major metabolic transformation is reduction of the 6-keto group, producing 6β-naltrexol. Human metabolic studies have identified free and conjugated 6β-naltrexol among the principal metabolites after naltrexone administration, and later work has demonstrated stereospecific enzymatic formation of this metabolite.

So several different questions need to be kept separate:

• What stereochemistry was present in the starting material?
• Which synthetic route was used?
• What stereochemical transformations occurred during manufacture?
• What chemical form was ultimately administered?
• What metabolites did the patient's own metabolism subsequently produce?
• What biological targets did the parent drug and metabolites interact with?

These are related questions, but they are not interchangeable.

The molecule in the bottle is only the beginning

This perspective is particularly useful when thinking about LDN.

A low dose of pharmaceutical naltrexone enters a biological system in which the parent compound and its metabolites can have different concentrations, half-lives and pharmacological properties. Researchers are also continuing to investigate actions beyond classical opioid-receptor antagonism.

That means the manufacturing history of a particular batch can be a fascinating pharmaceutical-chemistry question without, by itself, providing a complete explanation of what happens after a patient takes the medicine.

The same principle applies in the other direction: observations about patients cannot, on their own, establish which stereochemical or molecular mechanism is responsible.

Clinical observations and mechanistic chemistry answer different questions.

What does this mean for people taking LDN?

The scientific understanding of naltrexone has changed considerably since 2008. That does not mean that every historical observation about LDN has suddenly been invalidated.

Patients and clinicians have reported benefits associated with LDN, and LDN has been investigated in clinical studies. At the same time, systematic reviews published in recent years have found that the clinical evidence remains limited or mixed for particular conditions, with calls for larger and better-standardised trials.

The appropriate scientific position is therefore neither to dismiss patient experience nor to treat reported benefit as proof of a particular mechanism.

An observation can be real even when its mechanism is not yet fully understood.

That is one of the reasons continued research matters.

So does the manufacturing debate matter?

Scientifically, yes.

It is worth knowing which stereochemical forms are possible, how different synthetic routes produce them, how (+)- and (−)-naltrexone differ pharmacologically, and how the human body transforms naltrexone after administration.

For the LDN Research Trust, these are questions worth encouraging researchers to investigate.

But the available evidence does not justify turning one historical manufacturing account into a universal statement about all naltrexone, all manufacturers, or every batch supplied to patients.

The public patent record gives us valuable historical context. Modern synthetic chemistry shows that there are multiple routes to naltrexone and that stereochemical control can be introduced in different ways. Human pharmacology shows that metabolism adds another layer of stereoselective chemistry.

Perhaps the most useful conclusion is therefore also the simplest:

There probably was never a single, simple chemistry story.

The manufacturing chemistry matters. The stereochemistry matters. The metabolites matter. And the clinical evidence matters.

But ultimately, the molecule in the bottle is only the beginning of the pharmacological story.

Scientific editorial note

This article distinguishes documented chemistry from historical recollection and from hypotheses about LDN mechanisms. References to patient-reported benefit describe reported experience, not proof of efficacy or mechanism. The article is intended as educational material and is not medical advice.

References

1. Sanofi-Aventis France. WO2008/034973A1, Process for preparing N-alkyl naltrexone halides. French priority 21 September 2006; published 27 March 2008.

2. Dongbang S, Pedersen B, Ellman JA. Asymmetric synthesis of (−)-naltrexone. Chemical Science. 2019;10:535–541. doi:10.1039/C8SC03748E.

3. Wall ME, Brine DR, Perez-Reyes M. The metabolism of naltrexone in man. NIDA Research Monograph. 1981;28:105–131.

4. Wall ME, Brine DR, Perez-Reyes M. Metabolism and disposition of naltrexone in man after oral and intravenous administration. Drug Metabolism and Disposition. 1981;9(4):369–375.

5. Hutchinson MR, et al. Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as antagonists of Toll-like receptor 4. British Journal of Pharmacology. 2015.

6. Liu B, et al. Dissecting the innate immune recognition of opioid inactive isomer (+)-naltrexone derived Toll-like receptor 4 antagonists. Journal of Chemical Information and Modeling. 2018.

7. Rassi-Mariani V, et al. The use of naltrexone in the treatment of chronic pain: a systematic review. Pain Management. 2024;14(8):453–463.

8. Vatvani AD, et al. Efficacy and safety of low-dose naltrexone for the management of fibromyalgia: a systematic review and meta-analysis of randomized controlled trials. Korean Journal of Pain. 2024;37(4):367–378.